Companies · Pharmaceuticals

NuSirt Sciences Inc.

NASHVILLE · Pharmaceuticals

Diligence memoA one-page analyst read on NuSirt Sciences Inc. — recommendation, valuation, rhythm, risks.
$8.1M
Total raised · real
3
Rounds
0.5×
Latest step-up
Top 51%
Sector rank · raised
Series A
Latest stage · inferred · Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

NuSirt Sciences Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.35× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.
Dormant
  • Last raise 9.6 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

NuSirt Sciences Inc. is one of 1610 Pharmaceuticals companies tracked from NASHVILLE. By capital raised it ranks mid-pack (ahead of 50% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
29
Investors (latest)
2012
Year incorporated
2016-11-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2015-05-07 Raised $2.1M (real) Modeled valuation $79M (est)$2.1M$79MSeed2015Series A · 2015-09-30 Raised $4.0M (real) Modeled valuation $124M (est)$4.0M$124MSeries A2015Series A · 2016-11-22 Raised $2.0M (real) Modeled valuation $62M (est)$2.0M$62MSeries A2016+$4.0M+$2.0MCumulative $8.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.1M · 2015
Series A$4.0M · 2015
Series A extension$2.0M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$61.9M
Base estimate est.
$2.3M
Conservative case
$336.8M
Upside case
$9.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $78.7M · 2015-05-072015Series A · modeled $123.9M · 2015-09-30Series A · modeled $61.9M · 2016-11-222016
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
9.6 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$5.2M/yr
Capital velocity
11.2 yr
On record since
2015
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.0× of median
This company$8.1M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.4× of median
This company$2.0M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.8× of median
This company$61.9M
Sector median$76.1M

Raised more than 50% of sector peers (real $). Modeled value above 46% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #70 of 88.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Arbutus Biopharma Corp · Series A Raised $15.0M · modeled $464.6M (est)Rvc 360, Llc · Series A Raised $15.0M · modeled $464.6M (est)Sterrx, Llc · Series A Raised $18.0M · modeled $464.6M (est)Ribometrix, Inc. · Series A Raised $18.5M · modeled $464.6M (est)Neuraltus Pharmaceuticals, Inc. · Series A Raised $40.6M · modeled $462.7M (est)SiteOne Therapeutics, Inc. · Series A Raised $16.1M · modeled $460.3M (est)Right Value Drug Stores, Inc. · Series A Raised $13.3M · modeled $411.9M (est)USWM Enterprises, LLC · Series A Raised $12.2M · modeled $376.7M (est)Satsuma Pharmaceuticals, Inc. · Series A Raised $12.1M · modeled $375.8M (est)Chase Pharmaceuticals Corp · Series A Raised $26.5M · modeled $370.9M (est)Vitruvias Therapeutics, Inc. · Series A Raised $12.4M · modeled $356.2M (est)Vyome Therapeutics Inc. · Series A Raised $14.5M · modeled $351.1M (est)NuSirt Sciences Inc. (this company) Raised $8.1M · modeled $61.9M (est)NuSirt Sciences Inc.
CompanyStageRaised · realValue · estvs peer med.
Arbutus Biopharma CorpSeries A$15.0M$464.6M2.61×
Rvc 360, LlcSeries A$15.0M$464.6M2.61×
Sterrx, LlcSeries A$18.0M$464.6M2.61×
Ribometrix, Inc.Series A$18.5M$464.6M2.61×
Neuraltus Pharmaceuticals, Inc.Series A$40.6M$462.7M2.60×
SiteOne Therapeutics, Inc.Series A$16.1M$460.3M2.59×
Right Value Drug Stores, Inc.Series A$13.3M$411.9M2.31×
USWM Enterprises, LLCSeries A$12.2M$376.7M2.12×
Satsuma Pharmaceuticals, Inc.Series A$12.1M$375.8M2.11×
Chase Pharmaceuticals CorpSeries A$26.5M$370.9M2.08×
Vitruvias Therapeutics, Inc.Series A$12.4M$356.2M2.00×
Vyome Therapeutics Inc.Series A$14.5M$351.1M1.97×
NuSirt Sciences Inc. this companySeries A$8.1M$61.9M0.35×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.1M2015-05-07$10.3M$78.7M85%
Series A$4.0M2015-09-30$18.2M$123.9M85%
Series A$2.0M2016-11-22$9.1M$61.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.1M2015-05-07
    • First recorded raise — entered as Seed.
    • 26 investors on this round.
  2. Series A$4.0M2015-09-30
    • Came back fast: 5 mo vs the ~13 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • 28 investors on this round.
  3. Series A$2.0M2016-11-22
    • Raised 14 mo later, in step with the ~13 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 29 investors on this round.
Intelligence
2017 ~Q3
Modeled next raise · ~9mo cadence
$2.0M
Modeled next size est.range $2.0M$3.2M
0.5×
Last step-up
$5.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
JOSEPH C. COOK, JR.4 other2015-05
Barbara Cannon1 other2015-05
Brian C. Laden2015-05
Eric C. Satz2015-05
Michael C. Zemel2015-05
Vaughn C. Bryson2015-05
Registry & provenance

NuSirt Sciences Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1642239
SEC CIK
2012
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Skyline Vet Pharma, Inc.PharmaceuticalsSeries A$6.4M$155.2Mnetwork1 shared operator · same sector · same stage
Kereos, IncPharmaceuticalsSeries A$7.7M$34.9Msame sector · same stage
Companion Spine, LLCPharmaceuticalsSeries A$8.5M$58.9Msame sector · same stage
NBO Pharma Inc.PharmaceuticalsSeries A$7.6M$25.7Msame sector · same stage
KinDex Pharmaceuticals, Inc.PharmaceuticalsSeries A$7.5M$27.9Msame sector · same stage
Optikira, LLCPharmaceuticalsSeries A$8.8M$83.6Msame sector · same stage
Pharma Solutions USA, Inc. DBA LighthouseAIPharmaceuticalsSeries A$7.2M$56.1Msame sector · same stage
Kirax CorpPharmaceuticalsSeries A$7.0M$25.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Nuvation Bio Inc.PharmaceuticalsSeries D+$9.7B85%
ProVet Investment Holdings, LLCPharmaceuticalsSeries A$11.2M82%
Nu-Med Plus, Inc.BiotechnologyPre-Seed$36.5M82%
AyuVis Research, Inc.PharmaceuticalsSeed$28.3M81%
Navitor Pharmaceuticals, Inc.PharmaceuticalsSeries B$686.4M81%
Med-Tech Investments Group, LLCPharmaceuticalsSeed$98.9M80%
NuvOx Therapeutics, Inc.PharmaceuticalsSeed$1.0M80%
Paragon Biosciences Qlarity Capital, Inc.PharmaceuticalsSeries B$510.1M80%
Frequently asked
How much funding has NuSirt Sciences Inc. raised?
NuSirt Sciences Inc. has raised approximately $8.1M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is NuSirt Sciences Inc.'s estimated valuation?
Provath's modeled valuation for NuSirt Sciences Inc. is approximately $61.9M (modeled range $2.3M–$336.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is NuSirt Sciences Inc. at?
NuSirt Sciences Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Nov 22.
What does NuSirt Sciences Inc. do and where is it based?
NuSirt Sciences Inc. operates in the Pharmaceuticals sector, based in NASHVILLE.
Explore related

See where NuSirt Sciences Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at NuSirt Sciences Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.